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Abstract Obesity-associated diabetes (‘‘diabesity’’) in
mouse strains is characterized by severe insulin resistance,
hyperglycaemia and progressive failure, and loss of beta
cells. This condition is observed in inbred obese mouse
strains such as the New Zealand Obese (NZO/HlLt and
NZO/HlBomDife) or the TALLYHO/JngJ mouse. In lean
strains such as C57BLKS/J, BTBR T?tf/J or DBA/2 J
carrying diabetes susceptibility genes (‘‘diabetes suscepti-
ble’’ background), it can be induced by introgression of the
obesity-causing mutations Lep \ob[ (ob) or Lepr \db[
(db). Outcross populations of these models have been
employed in the genome-wide search for mouse diabetes
genes, and have led to positional cloning of the strong
candidates Pctp, Tbc1d1, Zfp69, and Ifi202b (NZO-derived
obesity) and Sorcs1, Lisch-like, Tomosyn-2, App, Tsc2, and
Ube2l6 (obesity caused by the ob or db mutation). Some of
these genes have been shown to play a role in the regula-
tion of the human glucose or lipid metabolism. Thus, dis-
section of the genetic basis of obesity and diabetes in
mouse models can identify regulatory mechanisms that are
relevant for the human disease.
Introduction: rationale for the use of mouse models
in the investigation of the metabolic syndrome
The human metabolic syndrome is a complex combination
of the traits visceral obesity, dyslipoproteinemia, hyper-
tension, and insulin resistance which have life-shortening
consequences such as type 2 diabetes and atherosclerosis.
Inbred mouse strains, e.g., the New Zealand Obese mouse
(NZO/HlLt and NZO/HlBomDife; NZO), the C57KS/J-db/
db mouse, or the TALLYHO/JngJ (TALLYHO; TH)
mouse, present a similar syndrome of obesity-associated
insulin resistance, beta-cell failure, and ultimately chronic
hyperglycaemia. For this type 2 diabetes-like condition, the
term diabesity was coined, and it appears reasonable to
assume that many, if not all, pathogenetic mechanisms
leading to hyperglycaemia are similar in mice and humans.
Therefore, mouse models have been widely used to
investigate the pathogenesis of the metabolic syndrome,
and particular efforts have been made to identify the gene
variants that are responsible for the traits obesity and dia-
betes (beta cell loss). Because of their much higher dia-
betes susceptibility, male mice were used exclusively in
almost all studies.
A second advantage of the mouse model is that breeding
experiments are possible that lead to the localization of
disease genes. By that approach, a mutant gene responsible
for extreme obesity in the ob/ob mouse was cloned and
shown to encode leptin, an anorexigenic peptide secreted
from the adipocyte (Zhang et al. 1994). This landmark
discovery was soon followed by identification of other
diabesity genes in monogenic mutant strains, namely the db
(leptin receptor), agouti yellow, tubby, fat, and mahogany
mutations (Friedman 1997; Leibel et al. 1997). These
findings led to the elucidation of the neuroendocrine reg-
ulation of hunger and satiety controlled by peptides such as
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MSH and NPY (Woods and D’Alessio 2008). Subse-
quently, it was shown that mutations of human orthologs
(LEP, LEPR) or of functionally associated genes (POMC,
MCR4) produced phenotypes comparable with that of the
respective mouse models (Clement et al. 1998; Santini
et al. 2009).
The third advantage of the mouse model is that after
identification of a candidate gene, direct genetic evidence
for its involvement in a pathophysiology can be obtained in
mice, but very rarely in humans. Thus, inbred mouse
models are ideally suited for the investigation of the
obesity-associated diabetes. However, the genetic homo-
geneity of the inbred strains is not only an advantage, it
also limits their potential. Individuals of an inbred mouse
line are genetically identical, and it cannot be expected that
a single strain carries more than a small portion of all
relevant gene variants. Currently, more than 2000 mouse
QTL for different traits have been identified in crosses
between inbred stains, but only about 1 % has been char-
acterized on molecular level (Flint et al. 2005). Thus, more
than one model and new resources, e.g., systems biology
may be required for a complete genetic analysis of complex
traits. Previous and ongoing research supports the view that
the combination of individual genomes—by intercross of
inbred strains and by the generation of congenic lines—
will reveal effects of many more genes and gene interac-
tions than can be observed in a single inbred strain.
Because the cross-breeding experiments are time consum-
ing and expensive, selecting the ‘‘right’’ models of the
obesity-associated diabetes is of crucial importance (Leiter
2009). Another advantage of mouse studies in comparison
to human studies is the ability to control the environment
and to investigate effects of diets, exercise, and intestinal
microbiota.
Polygenic basis of ‘‘diabesity’’ in mice: the interaction
of obesity and diabetes genes
Obesity-associated diabetes (‘‘diabesity’’) is due to inter-
action of genes causing obesity with diabetes genes. This
conclusion is based on findings indicating that obesity is a
necessary but not sufficient condition for the type 2 dia-
betes-like hyperglycaemia: Obese mice are insulin resistant
and therefore more or less glucose intolerant, but in some
strains such as C57BL/6J-ob/ob, insulin resistance is
compensated by hyperinsulinemia and beta cell hyperpla-
sia, and plasma glucose is only moderately elevated. Other
models such as C57BLKS/J-db/db and NZO present overt
diabetes mellitus as defined by a threshold of 16.6 mM
(300 mg/dl) plasma glucose (Leiter et al. 1998); mice
crossing this threshold usually exhibit progressive failure
and subsequent apoptosis of beta cells. This type 2
diabetes-like condition is not due to the obesity-causing
gene variants but to other genes in the genetic background
of the strain, which cause obesity-associated diabetes. The
severe and early onsetting diabetes of the C57BLKS/J-db/
db strain is due to the C57BLKS/J background, since mice
carrying the db mutation on the C57BL/6J background are
not diabetic (Stoehr et al. 2000). Conversely, C57BL/6J-
ob/ob mice are normoglycemic, whereas introgression of
the ob mutation into the C57BLKS/J background produced
a severely diabetic strain (Coleman 1978). Furthermore, it
has been shown that in crosses of lean, normoglycaemic
strains with diabetic strains the lean strain can introduce
variants that markedly aggravate the diabetic phenotype
(Leiter et al. 1998; Plum et al. 2000).
Thus, lean mouse strains can be diabetes-susceptible
(e.g. C57BLKS/J, BTBR T?tf/J, NON/Lt) or diabetes-
resistant (e.g. C57BL/6J, 129/SvJ), as defined by the phe-
notype of the strain when an obesity-causing mutation has
been introduced (Herberg and Leiter 2001). Consequently,
lean strains can be valuable models for identification, and
considerable efforts have been made to identify the genes
responsible for this metabolic dichotomy. Furthermore,
there is a second conclusion from the above-described
findings: since obesity is required for the penetrance of
diabetes genes, their identification by random or targeted
mutagenesis requires introduction of obesity genes in a
‘‘reporter’’ cross.
Experimental strategy for identification of mouse genes
causing obesity and diabetes
The conventional strategy for identification of mouse dis-
ease genes is the genome-wide linkage analysis of outcross
populations. This approach led to numerous susceptibility
loci (quantitative trait loci, QTL) of obesity and diabetes-
related traits such as body weight, fat mass, plasma glucose
or insulin levels, and beta cell mass (for review and meta-
analysis of these studies see Wuschke et al. 2007; Schmidt
et al. 2008). So far, only few responsible gene variants have
been identified in these QTL. Because of the complex
interaction of genes, a particular locus may be detected in
one intercross, and may be hidden in another. Conventional
strategy of positional cloning then requires the introgres-
sion of a locus in a different strain, or into the lean, non-
diabetic breeding partner, and subsequently the definition
of a critical chromosomal region by further inbreeding of
the subcongenic line. When available, chromosome sub-
stitution strains and congenic lines generated thereof allow
an analysis of the architecture of a complex QTL, and a
refinement of the QTL into very small segments (Nadeau
et al. 2000; Yazbek et al. 2011). The critical region can
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then be investigated by sequence analysis and functional
characterization of its genes.
This strategy can considerably reduce the number of
candidates, because it safely excludes genes not present in
the critical region. In our hands, the generation of sub-
congenic strains was successful in the positional cloning of
the obesity genes Tbc1d1 (Chadt et al. 2008) and Ifi202b
(Vogel et al. 2012) and the diabetes gene Zfp69 (Scher-
neck, et al. 2009). However, the strategy is not always
feasible because the phenotype may be lost by the isolation
of the responsible gene on a different background. In these
cases, technologies such as mRNA profiling that allow the
investigation of thousands of genes can be used for a search
in the whole QTL. Furthermore, such a systems biology
approach combining genetic (mapping) and functional
(gene expression) data can analyze interactions between
QTL and leads not only to plausible candidates but also to a
mechanistic understanding of the pathogenesis (Lusis et al.
2008; Ferrara et al. 2008; Keller et al. 2008; Wang et al.
2011; Davis et al. 2012). Metabolomics data may also be
combined with the genetic information and can lead to
candidates as well as to mechanistic insight. In addition,
sequence comparisons of whole genome are feasible and
may lead to the identification of a responsible gene, if an
assay is available that proves loss or gain of its function.
Refining of a locus by mapping haplotype blocks is a
possibility but may lead to wrong information when the
causal mutation is ‘‘younger’’ than the haplotype block it is
located in.
Obviously, outcross populations of only two strains
cannot reflect the full complexity of polygenic traits and
diseases. Thus, the collaborative cross was established
which is a large panel of recombinant inbred strains
derived from a set of 8 genetically diverse founder strains
(Churchill and Complex Trait Consortium 2004). This
panel might also help to elucidate the genetic basis of
obesity, insulin resistance, and diabetes. However, it should
be noted that the strains of the panel might be too lean to
show failure and apoptosis of beta cells. More recently,
Parks et al. (2013) performed a systems genetic study
comparing more than 100 inbred mouse strains: genome-
wide genotyping (GWAS) of these strains identified 11
genes that were significantly associated with obesity (e.g.
Sfrp5, Chrebp, Tmem160), and indicated considerable
overlap with loci identified in human GWAS.
For the identification of obesity genes, genome-wide
mutagenesis (Drosophila melanogaster) and siRNA
approaches (Cenorhabditis elegans) can be helpful. Genes
that were found to be associated with adiposity in these
studies can be validated in the mouse. By this approach, we
identified a variant of the cholesterol transporter Abcg1
from NZO which increased adiposity (Buchmann et al.
2007).
Polygenic mouse models of the metabolic syndrome
The New Zealand obese mouse
New Zealand obese (NZO) mice present a syndrome of
morbid obesity, insulin resistance, hypertension, and
hypercholesterolemia which resembles the human meta-
bolic syndrome (Bielschowsky and Bielschowsky 1953;
Herberg and Coleman 1977; Ortlepp et al. 2000; Kluge
et al. 2012). Obesity is due to a moderately increased food
intake and reduced energy expenditure with reduced body
temperature (Koza et al. 2004; Ju¨rgens et al. 2006). As a
consequence of the syndrome, male NZO mice develop
type 2 like diabetes characterized by marked hyperglyca-
emia and hyperinsulinemia at earlier age (8–12 weeks),
and later on by low serum insulin levels associated with
beta-cell destruction (Crofford and Davis 1965; Leiter et al.
1998; Ju¨rgens et al. 2006). The syndrome has a polygenic
basis, and outcross progeny of the strain as well as gen-
eration of subcongenic lines has previously been used for
identification of genes associated with adiposity, hyper-
cholesterolemia, and hyperglycaemia (Leiter et al. 1998;
Reifsnyder et al. 2000; Plum et al. 2000; Kluge et al. 2000;
Taylor et al. 2001; Reifsnyder and Leiter 2002; Plum et al.
2002; Giesen et al. 2003; Vogel et al. 2009; Vogel et al.
2012).
Strains rendered obese by introgression of mutations
causing monogenic obesity
The loss-of-function mutations in the leptin (Lep \ob[;
ob) and in the leptin receptor gene (Lepr \db[; db) cause
morbid obesity, and depending on the background, may
cause severe hyperglycaemia. As was outlined above, lean
strains may carry diabetogenic or diabetes-suppressing
alleles which produce a phenotype only after introgression
of the adipogenic mutations. Thus, several crosses were
performed with lean diabetes-susceptible strains
(C57BLKS/J, BTBR, DBA/2J, BALB/c) which were
crossed with the diabetes-resistant C57BL/6J (B6) strain.
Breeding pairs for generation of F2 or backcross popula-
tions had to be heterozygous for the ob or db mutation, and
homozygous progeny was analyzed. This strategy led to
identification of the candidate genes Sorcs1 (BTBR; Clee
et al. 2006), Lisch-like (DBA/2J; Dokmanovic-Chouinard
et al. 2008), Tomosyn-2 (BTBR T?tf/J; Bhatnagar et al.
2011), and App (BTBR T?tf/J; Tu et al. 2012) which are
presumably responsible for the beta cell phenotype of the
progeny. In addition, candidate genes causing fatty liver
(Tsc2; Wang et al. 2012) or suppressing obesity (Ube2l6;
Marcelin et al. 2013) were identified in crosses with
BALB/c, respectively. An advantage of this model is that
obesity in the ob/ob or db/db progeny is less variable than
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in outcross populations of polygenic strains. A disadvan-
tage is that chromosomal regions close to the ob or db locus
co-segregate with the mutations and cannot be studied in
these crosses. Another disadvantage is that the complete
absence of leptin signaling produces a unique genetic
background which is probably not descriptive of human
diabesity where the leptin and leptin receptor axis is at least
partially intact.
The TALLYHO mouse
The TALLYHO/JngJ (TH) mouse strain was generated by
selective breeding for hyperglycemia from an outbred
colony of mice (Kim and Saxton 2012). TH mice are obese,
hyperinsulinemic, and hyperlipidemic. Similar to NZO,
male TH mice develop severe hyperglycaemia (400 mg/dl
at 16 weeks of age). Obesity is less pronounced than in
NZO (35 g at weak 16), and, in contrast to NZO, blood
pressure of TH mice is normal. Analysis of F2 backcross
and intercross populations revealed numerous loci and
epistatic interactions accounting for the hyperglycaemia,
obesity, and hypertriglyceridemia in TH mice (Kim et al.
2001; Kim et al. 2005; Stewart et al. 2010). Congenic mice
carrying the Chr 6 locus on the B6 background confirmed
the QTL for obesity (Kim et al. 2005) and were further
analyzed (Stewart et al. 2012), but have not yet led to a
candidate gene. A comparison of the TH strain with a di-
abesity model derived from the NZO and NON strains
(NONcNZO10Lt/J) revealed remarkable similarities in
spite of the clear genetic differences (Leiter et al. 2013).
Lean strains rendered obese by dietary intervention
Moderate obesity can be induced in some lean strains by
feeding a high fat and/or sugar containing diet instead of
chow. Under these conditions, insulin resistance, hyperin-
sulinemia, and impaired glucose tolerance develops.
Numerous crosses between lean strains such as C57BL/6J
and C3H/HeJ (Toye et al. 2005; Li et al. 2012) kept on an
adipogenic diet were performed in order to map the genes
responsible for obesity and glucose intolerance (reviewed
by Wuschke et al. 2007; Schmidt et al. 2008). Furthermore,
several other crosses, e.g., between B6 and CAST mice,
noted for its low fat intake and preference for carbohy-
drates, have been generated to clarify the pathogenesis of
increased energy intake and obesity, and were character-
ized on different adipogenic or atherogenic diets (Smith
Richards et al. 2002; Estrada-Smith et al. 2004; Farber
et al. 2009). It has to be noted that diabetes (severe hy-
perglycaemia [300 mg/dL), and beta cell disruption does
not occur in these models. Thus, identification of the genes
responsible for the diabetic phenotype may require the
models of morbid obesity described above.
Candidate genes associated with obesity and diabetes
that were identified in NZO and NZO-derived outcross
populations
All adipogenic and diabetogenic gene variants identified in
outcross populations of obese mice are listed in Table 1,
and their putative sites of action are shown in Fig. 1.
Phosphatidyl choline transfer protein (Pctp)
The characterization of an outcross population of NZO/HI
with NON/Lt mice led to the identification of a major QTL
for hyperglycaemia and hypoinsulinemia on Chr 11
(Nidd3) (Leiter et al. 1998), and to the finding that NZO
mice exhibit an impaired phosphatidyl choline metabolism
(Pan et al. 2006a). The QTL comprises the gene encoding
phosphatidyl choline transfer protein (PC-TP) which is a
specific phosphatidyl choline-binding protein and regulates
hepatic lipid metabolism. Sequencing and functional
studies indicated that NZO carries an inactive variant
(R120H) which could be responsible for the diabetogenic
effect of Nidd3 (Pan et al. 2006b). Recently, it was reported
that siRNA-mediated knockdown, genetic ablation of Pctp
or chemical inhibition of PC-TP increases insulin sensi-
tivity by enhancing IRS2 activation (Ersoy et al. 2013).
TBC-domain protein 1 (Tbc1d1)
By genome-wide linkage analysis of an outcross population
of NZO/HIBomDife with lean SJL/J mice, a major QTL for
body weight was identified on chromosome 5 (Kluge et al.
2000). Additional outcross experiments suggested that the
responsible variant allele was an obesity suppressor unique
for SJL. Characterisation of recombinant congenic lines
carrying the variant on a C57BL/6J background defined a
critical region which was characterized by sequencing and
gene expression profiling. By this approach, it was shown
that SJL mice carry a loss-of-function variant of the Rab-
GAP Tbc1d1 generated by a 7 bp in-frame deletion which
produces a truncated protein (Chadt et al. 2008). Intro-
gression of the variant into NZO reduced body weight and
suppressed the development of diabetes. Knockdown of
endogenous Tbc1d1 in C2C12 muscle cells increased pal-
mitate uptake and oxidation, and reduced glucose oxidation
(Chadt et al. 2008). In C57BL/6J mice, the variant reduced
body weight, enhanced fat oxidation, and reduced glucose
oxidation (Chadt et al. 2008; Dokas et al. 2013). Thus,
adiposity and diabetes in obese mice are modified by dis-
ruption of Tbc1d1 through a metabolic shift from glucose
to fat oxidation. This mechanism may also explain the
association of the human R125W TBC1D1 variant with
obesity in Utah (Stone et al. 2006) and French families
(Meyre et al. 2008).
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Zinc finger protein 69 (Zfp69)
In the backcross population of NZO/HIBomDife with SJL/
J, an allele causing acceleration and aggravation of the
diabetes was mapped to distal chromosome 4 (Plum et al.
2000). The diabetogenic effect of the QTL was markedly
enhanced by NZO chromosome 5 (Tbc1d1) and by a high-
fat diet (Plum et al. 2002). Interval-specific congenic
introgression of SJL into diabetes-resistant C57BL/6J, and
subsequent reporter cross with NZO, led to the identifi-
cation of a critical interval of Chr 4 (2.1 Mbp) conferring
the diabetic phenotype (Scherneck et al. 2009). Analysis
of the 10 genes in the critical interval by sequencing and
qRT-PCR revealed a striking allelic variance of the zinc
finger domain transcription factor 69 (Zfp69); in NZO and
C57BL/6J, mRNA of Zfp69 was nearly undetectable. This
difference was due to the presence of a retroviral trans-
poson (IAPLTR1a) in intron 3 of NZO and C57BL/6J
which caused a premature polyadenylation of the Zfp69
mRNA (Scherneck et al. 2009). The transposon disrupts
the gene by formation of a truncated mRNA that lacked
the coding sequence for the KRAB and Znf-C2H2
domains of Zfp69. In contrast, the diabetogenic alleles
from SJL, NON, and NZB lacked the transposon and
generated a normal mRNA. When combined with the
C57BL/6J-ob/ob background, the diabetogenic SJL allele
of Zfp69 produced hyperglycaemia, reduced gonadal fat,
and increased plasma and liver triglycerides. mRNA levels
of the human orthologue of Zfp69 and ZNF642 were
significantly increased in adipose tissue from patients with
type 2 diabetes. Thus, Zfp69 is the most likely candidate
for the diabetogenic effect of Nidd/SJL. Expression of the
transcription factor in adipose tissue may play a role in the
pathogenesis of type 2 diabetes. In addition, retrotrans-
poson IAPLTR1a appears to contribute substantially to the
genetic heterogeneity of mouse strains, since it produced
aberrant mRNA species of 7 other genes (Scherneck et al.
2009).
Fig. 1 Pathophysiology of insulin resistance and type 2 diabetes with
beta-cell failure, and site of action of candidate genes identified by
positional cloning (highlighted in red). In response to increased food
intake and/or reduced energy expenditure, obesity develops as a major
cause of insulin resistance. Due to impaired signaling, insulin fails to
adequately suppress lipolysis in adipose tissue and release of glucose
and VLDL from the liver. Furthermore, fatty acid oxidation and
glucose uptake by the skeletal muscle are reduced, aggravating insulin
resistance and glucose intolerance. In the insulin resistant state,
pancreatic islets initially compensate by hyperplasia. However, in the
presence of diabetes genes apoptosis results in beta-cell loss and the
development of manifest type 2 diabetes
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Interferon-activated gene 202b (Ifi202b)
In an outcross F2 population of NZO/HIBomDife with the
diabetes-resistant C57BL/6J strain, a major QTL respon-
sible for obesity and hyperglycaemia was identified on
Chr 1 (Vogel et al. 2009). The QTL is particularly
important, since it interacted with the diabetogenic Zfp69
allele; the two loci accounted for almost all of the dia-
betes in the cross experiments NZO 9 B6.Cg-Nidd/SJL
designed to identify the diabetogenic gene in Nidd/SJL
(Scherneck et al. unpublished data). By introgression of
the chromosomal segment into B6, a critical region har-
boring approximately 30 genes was defined. Expression
profiling identified a major allelic difference: mRNA of
the interferon-activated gene 202b (Ifi202b) was generated
in NZO, but was undetectable in C57BL/6J. This differ-
ence was due to a microdeletion of approximately 30
Mbp in B6 which comprised exon 1 and the 5’-flanking
region of Ifi202b (Vogel et al. 2012). Whole genome
differential mRNA profiling indicated that the disruption
of Ifi202b reduced the expression of 17b-hydroxysteroid
dehydrogenase in adipose tissue. Overexpression and
knockdown of Ifi202b in 3T3-L1 preadipocytes indeed
induced or repressed expression of 17b-HSD. Since 17b-
HSD has previously been associated with obesity, Ifi202b
is a most plausible candidate gene contributing to the
effects of the QTL on Chr 1. It is worth noting that the
Ifi202b locus in addition to adiposity also modulates
behavioral traits, and that it maps to a QTL hotspot of
behavioral phenotypes identified in 32 different outcross
populations (Vogel et al. 2013).
Leptin receptor (Lepr)
Sequencing revealed that NZO mice carry a leptin receptor
variant with 4 amino acid exchanges including two non-
conservative substitutions (A720T, T1044I) (Igel et al.
1997). There is suggestive evidence that this variant con-
tributes to the obesity of the NZO strain, since the Lepr
locus appeared to enhance the effect of the QTL Nob1
(later identified as Tbc1d1) on body weight and serum
insulin in female (SJLxNZO)NZO backcross mice (Kluge
et al. 2000). Functional studies of the receptor variant
expressed in COS-7 cells indicated an only small reduction
of its signaling potential (Kluge et al. 2000). The contri-
bution of the receptor variant to the obesity syndrome of
the NZO mouse appears to depend on other adipogenic
alleles, since the variant is also present in the related New
Zealand Black (NZB) strain which shows neither obesity
nor insulin resistance. Furthermore, it has been suggested
that hyperphagia of NZO mice could be a consequence of
impaired brain uptake of leptin (Hileman et al. 2002).
ATP-binding cassette transporter G1 (Abcg1)
Association of the ATP-binding cassette transporter G1
(ABCG1) with obesity was discovered in a screening
approach that compared data from the Drosophila mela-
nogaster and mouse genomes (Buchmann et al. 2007). In a
random mutagenesis screen, Drosophila genes involved in
triglyceride storage were identified, and their mouse
orthologs that mapped to obesity QTL were further ana-
lyzed. Overexpression of the Drosophila orthologue of
Abcg1 generated lines of flies with increased triglyceride
stores. Abcg1 is located in a suggestive obesity QTL on
proximal Chr 17, and NZO mice carry an insertion of
multiple LXR-responsive elements that was associated
with higher expression of the gene in white adipose tissue.
Targeted disruption of Abcg1 in mice reduced adipose
tissue depots, decreased the size of the adipocytes, and
prevented high-fat diet-induced insulin resistance and fatty
liver. Furthermore, mRNA levels of the cholesterol-regu-
lated transcription factor LXRa and of its downstream
target ABCA1 were increased in adipose tissue of male
Abcg1-/- mice. Thus, it has been suggested that ABCG1
regulates triglyceride storage by controlling intracellular
cholesterol as a key regulator of gene expression in the
adipocyte (Buchmann et al. 2007).
Neuromedin U receptor 2 (Nmur2)
Sequencing of the known genes involved in the regulation of
energy balance led to the identification of a variant neu-
romedin U receptor 2 in NZO carrying two amino acid
substitutions (V190M and I202M) (Schmolz et al. 2007).
The Nmur2 gene is located in a suggestive obesity QTL on
chromosome 11, distal to the diabetes QTL Nidd3. Neu-
romedin U exerts an anorexigenic effect on meal frequency
that is blunted in NZO as compared with lean C57BL/6J mice
(15 vs. 60 % reduction in C57BL/6J). Transfection of
HEK293 cells with wild-type and variant Nmur2 cDNA
indicated a reduced signaling potential of the variant receptor
(EC50 of 3.0 ± 1.3 nM vs. 8.7 ± 3.9 nM of the NZO vari-
ant). These data suggest that resistance to the anorexigenic
effect of NmU contributes to the obesity of NZO mice, and
that this resistance may reflect an impaired signal transduc-
tion of the NZO NmuR2 variant (Schmolz et al. 2007).
Candidate genes identified in outcross populations
carrying the ob or db mutation
Sorcs1
In obese mice of an intercross between C57BL/6J-ob/ob
and BTBR T?tf/J mice (Clee et al. 2006), a major QTL on
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Chr 19 responsible for impaired insulin secretion and beta
cell degradation was identified. Introgression of the chro-
mosomal segment of B6 to the BTBR strain and analysis of
a series of subcongenic lines defined a critical region of
242 kb. In this interval, Sorcs1 was the only gene with
amino acid substitutions of altered expression, and was
thus considered the most likely candidate. SORCS1 binds
platelet derived growth factor, and it was suggested that the
gene has a role in expanding or maintaining the islet vas-
culature. SNPs in the human SORCS1 gene were found to
be associated with fasting insulin levels in the Mexican
American Coronary Artery Diseases cohort, and with dia-
betes risk in women of the San Antonio Family Diabetes
Study (Clee et al. 2006).
Lisch-like
In the obese F2 progeny of a C57BL/6J-ob/?x DBA/2J-ob/
?intercross, a QTL conferring diabetes (hyperglycaemia,
hypoinsulinemia, disrupted islet morphology) was mapped
to distal Chr 1 (Dokmanovic-Chouinard et al. 2008). The
diabetogenic allele was contributed by the DBA/2 J back-
ground. A critical region of 1.8 Mb in the QTL comprising
14 genes was identified with a series of subcongenic lines.
Of these, the gene Lisch-like was identified by mRNA
expression analysis and sequencing as the most likely
candidate. Knockdown of the gene in zebrafish produced a
dispersed phenotype of insulin-producing cells. In addition,
ENU-induced null mutation of Lisch-like produced a phe-
notype that was similar to that of the subcongenic lines
(Dokmanovic-Chouinard et al. 2008). So far, the function
of Lisch-like is completely unknown.
Tomosyn-2
In the intercross employed to identify Sorcs1 (see above), a
second type 2 diabetes locus was identified on Chr 16
(Bhatnagar et al. 2011). Introgression of BTBR T?Tf/J Chr
16 into the B6 background generated consomic mice which
exhibited elevated fasting glucose and lower insulin levels.
A critical region of 1.6 Mb was determined with subcon-
genic lines. The second phase of insulin secretion was
reduced in islets from congenic lines carrying the BTBR-
derived chromosomal segment. The most likely candidate
in the region was tomosyn-2 which exhibited a difference
in expression and a non-synonymous SNP within the
coding region. Overexpression of the BTBR variant of
Tomosyn-2 in INS1 cells inhibited insulin secretion. In
addition, the B6 variant appeared more susceptible to
proteasomal degradation (Bhatnagar et al. 2011). These
data suggest a major functional difference between the
variants which could be responsible for the diabetic
phenotype.
Tuberous sclerosis complex 2 (Tsc2)
In the C57BL/6J-ob/?x BTBR-ob/?intercross, a QTL for
fatty liver was mapped to Chr 17 (Wang et al. 2012). As the
most likely candidate gene responsible for this phenotype,
Tsc2 was identified. Tsc2 is an inhibitor of the target of
rapamycin, and is involved in cell growth and proliferation.
Heterozygous Tsc2 knockout mice exhibit an increased
expression of lipogenic genes in the liver. The allelic dif-
ference between BTBR and B6 is a coding SNP which
leads to an altered gene expression when transfected in
AML12 cells, and an altered proliferation of Ins1 cells
(Wang et al. 2012).
Amyloid precursor protein (App)
A comprehensive analysis of the interactions between
genotype, mRNA expression in 5 tissues, and plasma
insulin in obese mice of the B6 9 BTBR intercross (see
above) led to the identification of the Alzheimer gene App
as a candidate regulator of insulin secretion (Tu et al.
2012). App knockout mice exhibited increased insulin
secretion in response to glucose, suggesting mechanistic
similarities between the neurodegenerative disease and
type 2 diabetes (Tu et al. 2012).
Ubiquitin-conjugating enzyme E2L6 (Ube2l6)
The analysis of obese progeny of a (C57BL/6J ob/
? 9 BALB/c ob/?) 9 BALB/c ob/? backcross popula-
tion identified a BALB/c-derived QTL (Lipq1) on Chr 2
protecting against obesity by increased lipolysis and ATGL
(adipocytes triglyceride lipase) expression in adipose tissue
(Marcelin et al. 2012). By introgression of a segment of
C57BL/6J Chr 2 to the BALB/c background, a critical
interval of 9.8 Mbp was defined in which a nonsynony-
mous coding SNP in the gene encoding the ubiquitin-
conjugating enzyme E2L6 (Ube2l6) was identified. The
BALB/c allele of Ubc2l6 is hypomorph, and its expression
is markedly reduced in adipose tissue of BALB/c mice,
presumably causing the decrease in adipocyte size and
number. Accordingly, suppression of Ube2l6 in 3T3L1
adipocytes led to a reduced triglyceride accumulation
(Marcelin et al. 2013).
Genes associated with alterations of glucose homeostasis
identified in crosses between lean strains
Solute carrier family 35 member B4 (Slc35b4)
In crosses between C57BL/6J and A/J mice, a QTL on Chr
6 was identified which was responsible for 65 % of the
408 H.-G. Joost, A. Schu¨rmann: Type 2 diabetes (diabesity) in polygenic mouse models
123
body weight difference between the parental strains. A
chromosome 6 substitution strain was used to further dis-
sect this QTL with congenic and subcongenic lines, and
evidence for a complex architecture of 3 different loci
modifying body weight was obtained (Yazbek et al. 2011).
The subcongenic lines also indicated that the QTL was
responsible for a differences in insulin sensitivity and
glucose production between strains. In one of these loci,
the solute carrier family 35, member B4 (Slc35b4) was
identified as the most likely candidate. SLC35B4 is local-
ized in the Golgi membrane and facilitates transport of
UDP-xylose and UDP-N-acetylglucosamine into the Golgi
apparatus. Although no DNA sequence variation was
found, mRNA levels of Slc35b4 were 1.5-fold higher in
livers of subcongenic lines carrying the A/J allele.
Knockdown of Slc35b4 in liver cells suggested that the
gene is involved in the regulation of glucose production by
the liver (Yazbek et al. 2011).
Amyloid P component, serum (Apcs)
In an intercross between C57BL/6J and C3H/HeJ (C3H)
apoliporotein E-deficient mice, a QTL for fasting glucose
was mapped to distal Chr 1 (Li et al. 2012). Generation of
congenic strains that were challenged with a high-fat diet
confirmed the QTL. A gene (Apcs) located in the peak
region of the QTL was identified as a likely candidate
because of an allelic difference in its expression in liver.
Apcs encodes serum amyloid peptide, and protein levels in
serum increased in response to the high-fat diet. In addi-
tion, transgenic expression of Apcs from C3H reduced
glucose intolerance of B6.
Nicotinamide nucleotide transhydrogenase (Nnt)
Genome wide linkage analysis of a F2 intercross of
C57BL/6J 9 C3H/HeH identified a QTL on Chr 13 for
impaired insulin secretion due to a failure of glucose to
close KATP channels (Toye et al. 2005). The mitochondrial
proton pump Nnt is located in the peak region of the QTL,
and its expression was markedly lower in liver and islets of
the B6 strain due to a deletion of exons 7–11. Direct evi-
dence for the functional role of Nnt was obtained by siRNA
knockdown in MIN6 cells which markedly reduced glu-
cose-induced calcium influx and insulin secretion. Trans-
genic expression of the normal Nnt gene rescued the
defective insulin secretion and glucose tolerance of B6
mice (Freeman et al. 2006). These data suggest that
expression of a normally functioning NNT proton pump is
required for adequate insulin secretion. However, two more
recent studies reported contradictory results: Wong et al.
(2010) compared ob B6 substrains with normal or disrupted
Nnt and found no difference in glucose-stimulated insulin
secretion or insulin sensitivity, whereas Simon et al. (2013)
observed impaired glucose tolerance in B6/J versus B6/N
mice.
General conclusions and perspectives
The above summarized studies show that conventional
positional cloning is a valid strategy to identify mouse
genes that are responsible for obesity-associated diabetes.
By the generation of subcongenic lines of a QTL, if pos-
sible starting with chromosome substitution strains, then
small critical regions that harbor the gene(s) in question
can be identified with certainty. Sequence analysis and
mRNA profiling together with gene targeting in-vitro and
in-vivo may lead to a solid chain of evidence linking
sequence differences with altered molecular, cellular, and
physiologic function, thereby establishing causality for a
candidate gene. As far as the solidity of the evidence is
concerned, the strategy appears superior to the genome
wide association studies carried out in humans which, in
the absence of direct functional evidence, leads to sus-
ceptibility loci only. However, it should be noted that not
all of the published mouse candidate genes are based on
irrefutable direct evidence, and it would not be surprising if
some of them will turn out to represent false positives.
Furthermore, with the mouse strains employed so far, only
a part of the full complexity of diabesity may be accessible.
Thus, the panel of recombinant strains (Collaborative
Cross) derived from 8 founders which was generated by the
Complex Trait Consortium might become an important
research tool in the future.
A surprising result of the search for diabetes genes is
that there is little overlap between mouse genes identified
by positional cloning and human genes (loci) identified by
genome-wide association studies. So far, only a few obesity
mouse genes identified by GWAS overlap with human
obesity candidates (Parks et al 2013). A potential reason for
this limited overlap could be the difference in the degree of
homozygosity between humans and laboratory mice. Mice
have probably lost variants that produce severe phenotypes
when both alleles are affected. This does not mean that
results obtained from mouse models cannot be transferred
to the human disease: Most of the above-described genes
show relations with the human disease, e.g., by altered
gene expression or by involvement in a pathway that is also
connected with the human diabetes. Thus, mouse studies
lead to pathways that may be disrupted in both humans and
mice, and could thereby lead to novel therapeutic targets.
As an example, the identification of the adipogenic/diabe-
togenic alleles of Tbc1d1, Zfp69, and Ifi202b supports the
concept that fat oxidation and fat storage are crucial
determinants of obesity and diabetes. Thus, the
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identification of mouse obesity and diabetes genes is a
reasonable strategy to study the pathogenesis of both
mouse and human disease.
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